Population pharmacokinetics of Efavirenz in an unselected cohort of HIV-1-infected individuals [1]

Clinical Pharmacokinetics

Volumn 45, Issue 2, 2006, Pages 213-214

  Back, David J ^a   Owen, Andrew ^a   Khoo, Saye H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; GLYCOPROTEIN P; ISOENZYME; MULTIDRUG RESISTANCE PROTEIN 1;

AFRICAN AMERICAN; ALLELE; CAUCASIAN; CELL STRAIN CACO 2; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LETTER; PHARMACOGENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; HIV INFECTIONS; HIV-1; HUMANS; OXAZINES; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC;

EID: 33344458638     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200645020-00006     Document Type: Letter

References (14)

1. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44 (8): 849-61
2. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306 (1): 287-300
3. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40 (9): 1358-61
4. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15 (1): 1-5
5. Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40 (3): E22-3
6. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18 (18): 2391-400
7. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10 (4): 489-98
8. Desta Z, Ward BA, Flockhart DA, et al. Genetic variants of CYP2B6 decrease rate of efavirenz metabolism in vitro [abstract no. PI-61]. Clin Pharmacol Ther 2005; 77 (2): P24
9. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19 (7): 1038-45
10. Alonso-Villaverde C, Coll B, Gomez F, et al. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. Aids 2005; 19 (3): 341-2
11. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359 (9300): 30-6
12. Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8 (12): 531-4
13. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72 (1): 1-9
14. Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44 (11): 1273-81